Record Quarterly Concentrate Product Sales
Achieved the highest quarterly concentrate product sales, gross profit, and gross margin in Rockwell Medical's history during Q3 2024.
Profitability Achievements
Second consecutive quarter of profitability on a cash flow and adjusted EBITDA basis.
Significant Sales and Profit Growth
Net sales for Q3 2024 were $28.3 million, a 19% increase over Q3 2023, and a 31% increase excluding deferred revenue. Gross profit increased by 183% over the same period in 2023.
Distribution Agreement with Nipro Medical Corporation
Entered into a multimillion-dollar distribution agreement with Nipro Medical Corporation, with product purchasing minimums of $5 million for the first year.
Improved Financial Guidance for 2024
Increased guidance for 2024 net sales to $98-$101 million, gross profit to $15-$17 million, and adjusted EBITDA to $4-$5 million.
Cash Position Doubled
The company's cash position more than doubled from the end of Q1 2024.